The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata

Human Reproduction

Volumn 22, Issue 6, 2007, Pages 1696-1704

  Williams, A R W ^a   Critchley, H O D ^b   Osei, J ^b   Ingamells, S ^c   Cameron, I T ^c   Han, C ^d   Chwalisz, K ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Asoprisnil; Cell proliferation; Endometrium; Histopathology; Progesterone receptor

Indexed keywords

ASOPRISNIL; PLACEBO; PROGESTERONE RECEPTOR MODULATOR;

AMENORRHEA; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM; ENDOMETRIUM BIOPSY; FEMALE; FOLLICULAR PHASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MITOSIS; MORPHOLOGY; MULTICENTER STUDY; MYOMETRIUM; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SECRETION; STROMA CELL; UTERUS BLEEDING; UTERUS MYOMA;

EID: 34447305522     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem026     Document Type: Article

References (13)

1. Baird DT, Brown A, Critchley HO, William AR, Lin S and Cheng L (2003) Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 18, 61-68.
2. Brenner RM and Slayden OD (2005) Progesterone receptor antagonists and the endometrial antiproliferative effect. Semin Reprod Med 23,74-81.
3. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C and Larsen L (2005a) The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 20,1090-1099.
4. Chwatisz K, Parker RL, Williamson S, Larsen L, McCrary K and Elger W (2003) Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867 [abstract]. J Soc Gynecol Investig 10(Suppl 2),636.
5. Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G and Elger W (2005b) Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis [published erratum appears in Endocr Rev. 2005;26:703]. Endocr Rev 26,423-438.
6. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G and Chwalisz K (2003) Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy. Steroids 68,1019-1032.
7. Kelly RW, King AE and Critchley HO (2002) Inflammatory mediators and endometrial function-focus on the perivascular cell. J Reprod Immunol 57,81-93.
8. Mutter G and Ferenczy A (2002) Anatomy and histology of the uterine corpus. In Kurman R (ed.) Blaustein's Pathology of the Female Genital Tract. Springer-Verlag, New York, NY, pp. 383-419.
9. Narvekar N, Cameron S, Critchley HO, Lin S, Cheng L and Baird DT (2004) Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 89,2491-2497.
10. Noyes R, Hertig AT and Rock J (1950) Dating the endometrial biopsy. Fertil Steril 1,3-25.
11. Schubert G, Eiger W, Kaufmann G, Schneider B, Reddersen G and Chwalisz K (2005) Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 23,58-73.
12. Schwartz SM (2001) Invited commentary: Studying the epidemiology of uterine leiomyomata-past, present, and future. Am J Epidemiol 153,27-29
13. Spitz IM and Chwalisz K (2000) Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 65,807-815.